PL3196194T3 - Pochodne pirymidyny użyteczne jako selektywne inhibitory JAK3 i/lub JAK1 - Google Patents

Pochodne pirymidyny użyteczne jako selektywne inhibitory JAK3 i/lub JAK1

Info

Publication number
PL3196194T3
PL3196194T3 PL15842179T PL15842179T PL3196194T3 PL 3196194 T3 PL3196194 T3 PL 3196194T3 PL 15842179 T PL15842179 T PL 15842179T PL 15842179 T PL15842179 T PL 15842179T PL 3196194 T3 PL3196194 T3 PL 3196194T3
Authority
PL
Poland
Prior art keywords
pyrimidine derivatives
derivatives useful
jak1 inhibitors
selective jak3
jak3
Prior art date
Application number
PL15842179T
Other languages
English (en)
Inventor
Xianping Lu
Jindi Yu
Qianjiao YANG
Zhibin Li
Desi PAN
Song Shan
Jiangfei ZHU
Xianghui WANG
Xiangheng LIU
Zhiqiang Ning
Original Assignee
Shenzhen Chipscreen Biosciences, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chipscreen Biosciences, Ltd. filed Critical Shenzhen Chipscreen Biosciences, Ltd.
Publication of PL3196194T3 publication Critical patent/PL3196194T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
PL15842179T 2014-09-16 2015-09-14 Pochodne pirymidyny użyteczne jako selektywne inhibitory JAK3 i/lub JAK1 PL3196194T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410471468.9A CN105399685B (zh) 2014-09-16 2014-09-16 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用
PCT/CN2015/089499 WO2016041472A1 (zh) 2014-09-16 2015-09-14 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用
EP15842179.2A EP3196194B1 (en) 2014-09-16 2015-09-14 Pyrimidine derivatives useful as selective jak3 and/or jak1 inhibitors

Publications (1)

Publication Number Publication Date
PL3196194T3 true PL3196194T3 (pl) 2020-01-31

Family

ID=55465491

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15842179T PL3196194T3 (pl) 2014-09-16 2015-09-14 Pochodne pirymidyny użyteczne jako selektywne inhibitory JAK3 i/lub JAK1

Country Status (22)

Country Link
US (1) US10011571B2 (pl)
EP (1) EP3196194B1 (pl)
JP (1) JP6516305B2 (pl)
KR (1) KR101971887B1 (pl)
CN (1) CN105399685B (pl)
AU (1) AU2015317937B2 (pl)
BR (1) BR112017005113B1 (pl)
CA (1) CA2982881C (pl)
CY (1) CY1122423T1 (pl)
DK (1) DK3196194T3 (pl)
ES (1) ES2754403T3 (pl)
HK (1) HK1220975A1 (pl)
HR (1) HRP20191734T1 (pl)
HU (1) HUE045899T2 (pl)
LT (1) LT3196194T (pl)
PL (1) PL3196194T3 (pl)
PT (1) PT3196194T (pl)
RS (1) RS59467B1 (pl)
RU (1) RU2671195C2 (pl)
SI (1) SI3196194T1 (pl)
TW (1) TWI570109B (pl)
WO (1) WO2016041472A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4007752A1 (en) * 2019-08-02 2022-06-08 Amgen Inc. Kif18a inhibitors
BR112022008831A2 (pt) * 2019-11-08 2022-08-16 Shenzhen Chipscreen Biosciences Co Ltd Uso de composto na prevenção ou tratamento de doença de enxerto versus hospedeiro
AU2020390285A1 (en) * 2019-11-26 2022-06-23 Shenzhen Chipscreen Biosciences Co., Ltd. Composition containing aromatic heterocyclic compound in amorphous form, and preparation method therefor and use thereof
CN111297866B (zh) * 2020-03-09 2021-04-02 深圳微芯生物科技股份有限公司 一种包含jak3/jak1/tbk1抑制剂和甲氨蝶呤的药物组合物及其用途
BR112023021870A2 (pt) 2021-04-22 2023-12-19 Shenzhen Chipscreen Biosciences Co Ltd Composição farmacêutica que contém inibidor seletivo de jak3/jak1/tbk1 e uso médico da mesma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ539823A (en) 2002-11-28 2008-04-30 Schering Aktiengessellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
CN101421250A (zh) * 2006-01-30 2009-04-29 埃克塞里艾克西斯公司 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物
CA2673125C (en) * 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
PT2114900T (pt) * 2007-01-31 2019-01-17 Ym Biosciences Australia Pty Compostos à base de tiopirimidina e as suas utilizações
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101892989B1 (ko) * 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
DE102009001438A1 (de) * 2009-03-10 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
CN101906076B (zh) * 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
CN103073508B (zh) * 2011-10-25 2016-06-01 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法
CN104109127B (zh) * 2013-04-19 2019-11-05 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法

Also Published As

Publication number Publication date
AU2015317937B2 (en) 2018-10-04
HUE045899T2 (hu) 2020-01-28
TWI570109B (zh) 2017-02-11
WO2016041472A1 (zh) 2016-03-24
DK3196194T3 (da) 2019-10-28
US10011571B2 (en) 2018-07-03
BR112017005113A2 (pt) 2018-01-23
KR20170048593A (ko) 2017-05-08
EP3196194A4 (en) 2018-05-30
AU2015317937A1 (en) 2017-04-27
TW201612165A (en) 2016-04-01
US20170253566A1 (en) 2017-09-07
LT3196194T (lt) 2019-10-10
EP3196194B1 (en) 2019-08-07
ES2754403T3 (es) 2020-04-17
HRP20191734T1 (hr) 2019-12-13
CY1122423T1 (el) 2021-01-27
CN105399685A (zh) 2016-03-16
RU2671195C2 (ru) 2018-10-30
RU2017112299A (ru) 2018-10-17
CN105399685B (zh) 2018-05-22
CA2982881C (en) 2020-02-25
HK1220975A1 (zh) 2017-05-19
JP6516305B2 (ja) 2019-05-22
RU2017112299A3 (pl) 2018-10-17
SI3196194T1 (sl) 2019-12-31
EP3196194A1 (en) 2017-07-26
PT3196194T (pt) 2019-11-18
BR112017005113B1 (pt) 2023-02-14
JP2017527625A (ja) 2017-09-21
CA2982881A1 (en) 2016-03-24
RS59467B1 (sr) 2019-11-29
KR101971887B1 (ko) 2019-04-25

Similar Documents

Publication Publication Date Title
IL247949A0 (en) New histories of pyrazolopyrimidines and their use as malt1 inhibitors
HK1252752A1 (zh) 新型吡唑並嘧啶衍生物
IL291265A (en) Selective jak1 inhibitors and their uses
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
IL259150B (en) Pyrimidine derivative and use thereof
ZA201708568B (en) Pyrimidine derivatives as btk inhibitors and uses thereof
ZA201906875B (en) Jak1 selective inhibitors
IL259796A (en) Aza-benzimidazole inhibitors of pad4
EP3102571A4 (en) SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS
PL3196194T3 (pl) Pochodne pirymidyny użyteczne jako selektywne inhibitory JAK3 i/lub JAK1
HK1250028A1 (zh) 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途
HUE051898T2 (hu) Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
GB201509381D0 (en) Novel compounds and their use as kinase inhibitors
GB201505460D0 (en) Novel compounds and their use as kinase inhibitors
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors